What is he best known for?
The fields of study he is best known for:
Mark Ultsch mainly investigates Receptor, Biochemistry, Binding site, Peptide sequence and Antibody.
His Receptor research is multidisciplinary, incorporating perspectives in Extracellular, Phage display and Ternary complex.
In his work, Plasma protein binding is strongly intertwined with Biophysics, which is a subfield of Biochemistry.
His Peptide sequence study combines topics in areas such as Peptide bond, Subtilisin, Stereochemistry and Hydrogen bond.
His Stereochemistry research is multidisciplinary, relying on both Hydrolase and Hormone, Prolactin.
His research investigates the connection with Antibody and areas like Molecular biology which intersect with concerns in Complement system, Glycosylation, Cytotoxicity and Mutagenesis.
His most cited work include:
- Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. (2054 citations)
- Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule (821 citations)
- Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc (645 citations)
What are the main themes of his work throughout his whole career to date?
Biochemistry, Stereochemistry, Receptor, Biophysics and Antibody are his primary areas of study.
He works mostly in the field of Biochemistry, limiting it down to topics relating to In vivo and, in certain cases, In vitro.
As part of one scientific family, he deals mainly with the area of Stereochemistry, narrowing it down to issues related to the Structure–activity relationship, and often Drug discovery and ADME.
His work in Receptor addresses subjects such as Extracellular, which are connected to disciplines such as Ternary complex, Internal medicine and Endocrinology.
His Biophysics study combines topics from a wide range of disciplines, such as Binding protein, Plasma protein binding and Mechanism of action.
His Antibody research includes elements of Molecular biology and Glycosylation.
He most often published in these fields:
- Biochemistry (35.87%)
- Stereochemistry (27.17%)
- Receptor (19.57%)
What were the highlights of his more recent work (between 2012-2020)?
- Biochemistry (35.87%)
- Stereochemistry (27.17%)
- Antibody (14.13%)
In recent papers he was focusing on the following fields of study:
His main research concerns Biochemistry, Stereochemistry, Antibody, Lactate dehydrogenase and Pharmacology.
He incorporates Biochemistry and Identification in his research.
His work carried out in the field of Stereochemistry brings together such families of science as Structure–activity relationship, Binding site and Gene isoform.
Mark Ultsch combines subjects such as Receptor, Cancer research and Molecular biology with his study of Antibody.
His Receptor study deals with Effector intersecting with Mechanism of action.
His Pharmacology study which covers Enzyme that intersects with In vivo.
Between 2012 and 2020, his most popular works were:
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers (202 citations)
- Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition (100 citations)
- Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab. (93 citations)
In his most recent research, the most cited papers focused on:
Mark Ultsch mainly focuses on Biochemistry, Tyrosine kinase 2, Lactate dehydrogenase, Identification and Antibody.
His biological study spans a wide range of topics, including Thio- and Crystal structure.
Tyrosine kinase 2 combines with fields such as Structure–activity relationship, Genetics, Phenotype, Genomics and Gene in his work.
His studies deal with areas such as Potency, Benzamide, In vivo and Enzyme as well as Structure–activity relationship.
His Lactate dehydrogenase research is multidisciplinary, relying on both Stereochemistry and Pyrazine.
His Antibody research includes themes of Receptor, Cytokine and Mechanism of action.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
